Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Implications for manipulating immune response for some inflammatory disorders

Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory mediators.

14 May 2013

Drug cost disparities, small business worries continue to surround health law's implementation

The Associated Press reports on the emergence of concerns regarding the health law and drug cost disparities. Meanwhile, other news outlets report on how employers continue to have angst about the measure's price tag.

14 May 2013

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Biogen Idec announced today that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for the marketing approval of ELOCTATE (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.

13 May 2013

Who is responsible for retired football players' medical costs?

Who should bear the costs of football-related medical problems that arise years after retirement? This question is at the heart of Williams's case - and scores of others like it.

13 May 2013

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

Prednisone and non-steroidal anti-inflammatory drugs (NSAIDs) can be used for symptom control, but to prevent joint damage, we use disease-modifying anti-rheumatic drugs (DMARDs) including the cornerstone, methotrexate.

13 May 2013

Private insurers have cost Medicare almost $300 billion more over the life of the program

A study published online today finds that the private insurance companies that participate in Medicare under the Medicare Advantage program and its predecessors have cost the publicly funded program for the elderly and disabled an extra $282.6 billion since 1985, most of it over the past eight years. In 2012 alone, private insurers were overpaid $34.1 billion.

13 May 2013

Scientists identify new way to boost gene-silencing mechanism

A team led by scientists at The Scripps Research Institute (TSRI) has found how to boost or inhibit a gene-silencing mechanism that normally serves as a major controller of cells' activities. The discovery could lead to a powerful new class of drugs against viral infections, cancers and other diseases.

10 May 2013

Fat cells in knee secrete a protein linked to arthritis

Scientists have discovered that fat cells in the knee secrete a protein linked to arthritis, a finding that paves the way for new gene therapies that could offer relief and mobility to millions worldwide.

10 May 2013

First Edition: May 10, 2013

Todya's headlines include reports about efforts by the Obama administration to boost health exchange enrollment.

10 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

GHS patients to have access to doctors' notes through MyGeisinger online patient portal

More than 100,000 Geisinger Health System patients will have access to their doctors' notes for the first time through the secure MyGeisinger online patient portal when Geisinger expands OpenNotes in May due to the initiative's overwhelming success.

9 May 2013

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

POZEN announces revenue of $1.4 million for first quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2013.

8 May 2013

New treatment could potentially benefit Irish SLE patients, find researchers

Researchers from the Royal College of Surgeons in Ireland have discovered that a new treatment for the inflammatory condition, Systemic Lupus Erythmstosus could potentially benefit Irish patients who suffer from the condition.

8 May 2013

TSRI announces five-year agreement with Janssen to research on influenza virus

The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus.

7 May 2013

Rigel reports net loss of $25.6 million in first quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.

7 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Hospital for Special Surgery signs agreement with Brazilian healthcare organization

Clinical pathways and quality initiatives leading to world class outcomes are the foundation of a far-reaching agreement between New York-based Hospital for Special Surgery, the recognized leader in orthopedics, rheumatology and related specialties, and Amil Par, the largest managed healthcare organization in Brazil, on behalf of Hospitalys Ortopedia, its newly opened orthopedic center in Rio de Janeiro.

7 May 2013

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals, Inc. today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi.

3 May 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

3 May 2013

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Implications for manipulating immune response for some inflammatory disorders

Drug cost disparities, small business worries continue to surround health law's implementation

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Who is responsible for retired football players' medical costs?

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

Private insurers have cost Medicare almost $300 billion more over the life of the program

Scientists identify new way to boost gene-silencing mechanism

Fat cells in knee secrete a protein linked to arthritis

First Edition: May 10, 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

GHS patients to have access to doctors' notes through MyGeisinger online patient portal

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

POZEN announces revenue of $1.4 million for first quarter 2013

New treatment could potentially benefit Irish SLE patients, find researchers

TSRI announces five-year agreement with Janssen to research on influenza virus

Rigel reports net loss of $25.6 million in first quarter 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Hospital for Special Surgery signs agreement with Brazilian healthcare organization

Regeneron Pharmaceuticals expands ophthalmology portfolio

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Newsletters you may be interested in